Post [tmco]
Multiple [qnco]
Raloxifene [orch, phsu]
Evaluation [ftcn]
Trial [resa]
effects [qlco]
Raloxifene [orch, phsu]
treatment [ftcn]
glycemia [carb]
cardiovascular risk factor [dsyn]
Women [popg]
Type 2 Diabetes [dsyn]
Long-Term Effects [phpr]
Selective Estrogen Receptor Modulator [horm, phsu]
Raloxifene Hydrochloride [orch, phsu]
glycemia [carb]
Marker [clna]
Cardiovascular disease [dsyn]
postmenopausal [tmco]
Women [popg]
Diabetes Mellitus, Type 2 [dsyn]
Unknown [qlco]
Objective [inpr]
effects [qlco]
treatment [ftcn]
Raloxifene [orch, phsu]
mg/d [qnco]
placebo [topp]
glycemia [carb]
Marker [clna]
Cardiovascular disease [dsyn]
postmenopausal [tmco]
Women [popg]
Type 2 Diabetes [dsyn]
Methods [inpr]
included [ftcn]
Women [popg]
Multiple [qnco]
Raloxifene [orch, phsu]
Evaluation [ftcn]
Trial [resa]
Double [ftcn]
masked [resa]
Trial [resa]
randomized [resa]
Receive [qlco]
Raloxifene 60 MG [clnd]
placebo [topp]
N NOS [aapp, imft]
baseline [bodm]
Fasting [fndg]
Plasma glucose [lbpr]
Total Cholesterol [lbpr]
TC [geoa]
Measured [qlco]
participants [popg]
Glycated haemoglobin [aapp, bacs]
HbA [aapp, bacs]
High Density Lipoprotein Cholesterol [bacs, lipd]
Low Density Lipoprotein Cholesterol [bacs, strd]
Triglycerides [bacs, lipd]
Apolipoprotein A-I [aapp, bacs]
Apolipoprotein B [aapp, bacs]
Fibrinogen [aapp, bacs, phsu]
Assessed [acty]
participants [popg]
Select [acty]
larger [qnco]
Sites [spco]
